Gracell Biotechnologies Inc (GRCL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access GRCL Annual Balance Sheets →
Reviewing balance sheet figures over time helps illustrate how Gracell Biotechnologies Inc manages its resources, obligations, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2023)
(Dec 31 2022) 0 0 0
Assets
Cash & cash equivalent163.34
Short-term Investments, Total0.49
Cash & Short-term Investments163.00
Notes Receivable, Current4.94
Inventories0.23
Derivatives, Collateral, Regulatory, Deferred0.00
Prepaid Expense And Other Assets Current8.19
Total Current Assets172.03
Equipment/Property/Plant Net36.52
Tax Assets, Noncurrent0.00
Deferred, Prepaid and Other Assets, Noncurrent0.70
Other Assets, Noncurrent0.00
Total Assets190.02
Liabilities
Accrued Liabilities And Other Liabilities12.27
Short-term Debt14.20
Other Liabilities, Current0.26
Total Current Liabilities26.73
Long-term debt5.51
Total Long-term Debt5.51
Other liabilities, Noncurrent1.02
Total Liabilities33.26
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock405.77
Retained Earnings / Accumulated Deficit-265.32
Accumulated Other Comprehensive Income16.29
Other Equity16.29
Common Stockholder's Equity156.76
Total Stockholder's Equity156.76
Liabilities & Stockholder's Equity190.02
4 historic quarters locked

Sign in to unlock the full Gracell Biotechnologies Inc balance sheet history.

About Gracell Biotechnologies Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-23-049599

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.